is a glp 1 insulin GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Health Feed - Glp-1 Drugs

Ongoing research and investigational therapies, such as GIP/GLP-1/glucagon triple agonists, may inform future strategies for sustainable weight loss after discontinuation of weight loss pharmacotherapy

Its Phase 3 weight-loss figures (in the low-to-mid 20% range) and its late-2025 FDA filing belong to the combination product, not to standalone cagrilintide, which remains at the Phase 2 stage with a peer-reviewed monotherapy result of about 10.8% at 26 weeks

J., & Knop, F

8 , bvae164 (2024)

If you have two hands and can do it, you can stabilize the needle with one hand or you can just move your finger back and push all the medication in at a slow, steady rate